Vyjuvek, Topical Gene Therapy, Aids Wound Healing in DEB Trial

Vyjuvek, Topical Gene Therapy, Aids Wound Healing in DEB Trial

313949

Vyjuvek, Topical Gene Therapy, Aids Wound Healing in DEB Trial

Treatment with Vyjuvek (previously called B-VEC) — a topical gene therapy for dystrophic epidermolysis bullosa (DEB) — improved wound healing with good tolerability over six months, according to top-line results of the Phase 3 GEM-3 trial. “We are thrilled to announce positive results from our pivotal GEM-3 trial of VYJUVEK which showed that this topical gene therapy led to durable wound healing in dystrophic EB wounds,” Suma Krishnan, founder and chief operating officer of Krystal Biotech, Vyjuvek’s…

You must be logged in to read/download the full post.